Andrew Branagan, MD, discusses novel induction therapies being used with transplant to improve outcomes in patients with multiple myeloma.
Andrew Branagan, MD
Advertisement
Articles by Andrew Branagan, MD
Andrew Branagan, MD, discusses the role of autologous stem cell transplantation in patients with high-risk multiple myeloma.
Andrew Branagan, MD, discusses the results of the phase 3 TOURMALINE-MM3 trial in multiple myeloma.
Andrew Branagan, MD, discusses the research tandem transplants in patients with high-risk multiple myeloma.
Advertisement
Latest Updated Articles
Dr. Branagan on Tandem Transplants in Multiple MyelomaPublished: March 3rd 2020 | Updated:
Dr. Branagan on the Role of Transplant in High-Risk Multiple MyelomaPublished: May 28th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5